About 30% of cases, including those refractory to current therapies, could benefit from the use of drugs that target DNA damage response mechanisms in cancer cells. This is according to new research conducted by Candiolo’s IRCCS
Subscribe to our newsletter to stay informed
Towards new and more effective treatments for colorectal cancer. A new study by the IRCCS of Candiolo, Turin, has shown that about one in three cases, including the most aggressive and refractory tumors to current molecularly targeted therapies, could benefit from the use of drugs targeting damage response mechanisms. cancer cells. The study results have been published in the Journal of the American Academy of Cancer Research.
Source: TG 24 Sky
I am James Novak, a passionate and experienced news writer with the ultimate goal of delivering the most accurate and timely information to my readers. I work in the news department at a website dedicated to providing reliable and up-to-date information about technology. My articles are widely circulated, often featured on major publications, and have been read by millions of people around the world.